Influenza

The Lancet

Volumn 390, Issue 10095, 2017, Pages 697-708

  Paules, Catharine ^a   Subbarao, Kanta ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; ANTIVIRUS AGENT; NEW DRUG;

CLINICAL FEATURE; HUMAN; INFLUENZA A (H5N1); INFLUENZA A (H7N9); INFLUENZA VIRUS; LUNG DISEASE; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; REVIEW; SEASONAL INFLUENZA; VACCINATION; VIRUS TRANSMISSION; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANIMAL; CHEMISTRY; CHILD; COMMUNICABLE DISEASE; DISEASE CARRIER; DRUG APPROVAL; EUROPE; INFANT; INFLUENZA; INFLUENZA A VIRUS; INFLUENZA B VIRUS; ISOLATION AND PURIFICATION; MEDICAL RESEARCH; MIDDLE AGED; PANDEMIC; PRESCHOOL CHILD; TRANSMISSION; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT; ZOONOSIS;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANIMALS; ANTIVIRAL AGENTS; BIOMEDICAL RESEARCH; CHILD; CHILD, PRESCHOOL; COMMUNICABLE DISEASES, EMERGING; DISEASE RESERVOIRS; DRUG APPROVAL; DRUGS, INVESTIGATIONAL; EUROPE; HUMANS; INFANT; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; PANDEMICS; TREATMENT OUTCOME; UNITED STATES; VACCINATION; YOUNG ADULT; ZOONOSES;

EID: 85019701331     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)30129-0     Document Type: Review

References (139)

1. Bennett, JE, Dolin, R, Blaser, MJ, Mandell, Douglas, and Bennett's principles and practices of infectious diseases, 8th edn, 2015, Elsevier, Philadelphia, PA.
2. Cox, NJ, Subbarao, K, Global epidemiology of influenza: past and present. Annu Rev Med 51 (2000), 407–421.
3. Yang, L, Chan, KH, Suen, LK, et al. Age-specific epidemic waves of influenza and respiratory syncytial virus in a subtropical city. Sci Rep, 5, 2015, 10390.
4. Barker, WH, Mullooly, JP, Pneumonia and influenza deaths during epidemics: implications for prevention. Arch Intern Med 142 (1982), 85–89.
5. Biggerstaff, M, Cauchemez, S, Reed, C, Gambhir, M, Finelli, L, Estimates of the reproduction number for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature. BMC Infect Dis, 14, 2014, 480.
6. Jayasundara, K, Soobiah, C, Thommes, E, Tricco, AC, Chit, A, Natural attack rate of influenza in unvaccinated children and adults: a meta-regression analysis. BMC Infect Dis, 14, 2014, 670.
7. Thompson, WW, Shay, DK, Weintraub, E, et al. Influenza-associated hospitalizations in the United States. JAMA 292 (2004), 1333–1340.
8. Molinari, NA, Ortega-Sanchez, IR, Messonnier, ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25 (2007), 5086–5096.
9. Lafond, KE, Nair, H, Rasooly, MH, et al. Global role and burden of influenza in pediatric respiratory hospitalizations, 1982–2012: a systematic analysis. PLoS Med, 13, 2016, e1001977.
10. European Centre for Disease Prevention and Control. Influenza. http://ecdc.europa.eu/en/healthtopics/influenza/Pages/home.aspx, 2016 (accessed June 3, 2016).
11. Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza—United States, 1976–2007. MMWR Morb Mortal Wkly Rep 59 (2010), 1057–1062.
12. Cox, NJ, Subbarao, K, Influenza. Lancet 354 (1999), 1277–1282.
13. Memoli, MJ, Athota, R, Reed, S, et al. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis 58 (2014), 214–224.
14. Greenbaum, A, Chaves, SS, Perez, A, et al. Heavy alcohol use as a risk factor for severe outcomes among adults hospitalized with laboratory-confirmed influenza, 2005–2012. Infection 42 (2014), 165–170.
15. Horby, P, Nguyen, NY, Dunstan, SJ, Baillie, JK, An updated systematic review of the role of host genetics in susceptibility to influenza. Influenza Other Respir Viruses 7:suppl 2 (2013), 37–41.
16. Izurieta, HS, Thompson, WW, Kramarz, P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 342 (2000), 232–239.
17. Meijer, WJ, van Noortwijk, AG, Bruinse, HW, Wensing, AM, Influenza virus infection in pregnancy: a review. Acta Obstet Gynecol Scand 94 (2015), 797–819.
18. Schuurmans, MM, Isenring, BD, Jungo, C, et al. Clinical features and outcomes of influenza infections in lung transplant recipients: a single-season cohort study. Transpl Infect Dis 16 (2014), 430–439.
19. Xuan, Y, Wang, LN, Li, W, et al. IFITM3 rs12252 T>C polymorphism is associated with the risk of severe influenza: a meta-analysis. Epidemiol Infect 143 (2015), 2975–2984.
20. Van, Kerkhove MD, Mumford, E, Mounts, AW, et al. Highly pathogenic avian influenza (H5N1): pathways of exposure at the animal-human interface, a systematic review. PLoS One, 6, 2011, e14582.
21. Long, SS, Pickering, LK, Prober, CG, (eds.) Principles and practice of pediatric infectious diseases, 4th edn, 2012, Elsevier, China.
22. Shaw, ML, Palese, P, Orthomyxoviridae. Knipe, DM, Howley, PM, (eds.) Fields virology, 6th edn, 2013, Lippincott Williams and Wilkins, Philadelphia, PA, 1151–1184.
23. Tong, S, Zhu, X, Li, Y, et al. New world bats harbor diverse influenza A viruses. PLoS Pathog, 9, 2013, e1003657.
24. Kash, JC, Taubenberger, JK, The role of viral, host, and secondary bacterial factors in influenza pathogenesis. Am J Pathol 185 (2015), 1528–1536.
25. Shinya, K, Ebina, M, Yamada, S, Ono, M, Kasai, N, Kawaoka, Y, Avian flu: influenza virus receptors in the human airway. Nature 440 (2006), 435–436.
26. Kreijtz, JH, Fouchier, RA, Rimmelzwaan, GF, Immune responses to influenza virus infection. Virus Res 162 (2011), 19–30.
27. Killingley, B, Nguyen-Van-Tam, J, Routes of influenza transmission. Influenza Other Respir Viruses 7:suppl 2 (2013), 42–51.
28. Loeb, M, Dafoe, N, Mahony, J, et al. Surgical mask vs N95 respirator for preventing influenza among health care workers: a randomized trial. JAMA 302 (2009), 1865–1871.
29. Nikitin, N, Petrova, E, Trifonova, E, Karpova, O, Influenza virus aerosols in the air and their infectiousness. Adv Virol, 2014, 2014, 859090.
30. Tellier, R, Review of aerosol transmission of influenza A virus. Emerg Infect Dis 12 (2006), 1657–1662.
31. Brankston, G, Gitterman, L, Hirji, Z, Lemieux, C, Gardam, M, Transmission of influenza A in human beings. Lancet Infect Dis 7 (2007), 257–265.
32. Gustin, KM, Belser, JA, Wadford, DA, et al. Influenza virus aerosol exposure and analytical system for ferrets. Proc Natl Acad Sci USA 108 (2011), 8432–8437.
33. Alford, RH, Kasel, JA, Gerone, PJ, Knight, V, Human influenza resulting from aerosol inhalation. Proc Soc Exp Biol Med 122 (1966), 800–804.
34. Leung, NH, Zhou, J, Chu, DK, et al. Quantification of influenza virus RNA in aerosols in patient rooms. PLoS One, 11, 2016, e0148669.
35. Lindsley, WG, Noti, JD, Blachere, FM, et al. Viable influenza A virus in airborne particles from human coughs. J Occup Environ Hyg 12 (2015), 107–113.
36. Moser, MR, Bender, TR, Margolis, HS, Noble, GR, Kendal, AP, Ritter, DG, An outbreak of influenza aboard a commercial airliner. Am J Epidemiol 110 (1979), 1–6.
37. Wong, BC, Lee, N, Li, Y, et al. Possible role of aerosol transmission in a hospital outbreak of influenza. Clin Infect Dis 51 (2010), 1176–1183.
38. Cowling, BJ, Ip, DK, Fang, VJ, et al. Aerosol transmission is an important mode of influenza A virus spread. Nat Commun, 4, 2013, 1935.
39. Riley, RL, Airborne infection. Am J Med 57 (1974), 466–475.
40. Centers for Disease Control and Prevention. Influenza (flu). http://www.cdc.gov/flu/, 2016 (accessed Nov 16, 2016).
41. WHO. Influenza. http://www.who.int/topics/influenza/en/, 2016 (accessed Nov 16, 2016).
42. Bin-Reza, F, Lopez, Chavarrias V, Nicoll, A, Chamberland, ME, The use of masks and respirators to prevent transmission of influenza: a systematic review of the scientific evidence. Influenza Other Respir Viruses 6 (2012), 257–267.
43. Nicholson, KG, Clinical features of influenza. Semin Respir Infect 7 (1992), 26–37.
44. Ip, DK, Lau, LL, Chan, KH, et al. The dynamic relationship between clinical symptomatology and viral shedding in naturally acquired seasonal and pandemic influenza virus infections. Clin Infect Dis 62 (2016), 431–437.
45. Esposito, S, Daleno, C, Baldanti, F, et al. Viral shedding in children infected by pandemic A/H1N1/2009 influenza virus. Virol J, 8, 2011, 349.
46. Carrat, F, Vergu, E, Ferguson, NM, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 167 (2008), 775–785.
47. Rothberg, MB, Haessler, SD, Brown, RB, Complications of viral influenza. Am J Med 121 (2008), 258–264.
48. Gill, JR, Sheng, ZM, Ely, SF, et al. Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med 134 (2010), 235–243.
49. Shieh, WJ, Blau, DM, Denison, AM, et al. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol 177 (2010), 166–175.
50. Mistry, RD, Fischer, JB, Prasad, PA, Coffin, SE, Alpern, ER, Severe complications in influenza-like illnesses. Pediatrics 134 (2014), e684–e690.
51. Dwyer, DE, Smith, DW, Catton, MG, Barr, IG, Laboratory diagnosis of human seasonal and pandemic influenza virus infection. Med J Aust 185:suppl 10 (2006), 48–53.
52. Boivin, G, Hardy, I, Tellier, G, Maziade, J, Predicting influenza infections during epidemics with use of a clinical case definition. Clin Infect Dis 31 (2000), 1166–1169.
53. Call, SA, Vollenweider, MA, Hornung, CA, Simel, DL, McKinney, WP, Does this patient have influenza?. JAMA 293 (2005), 987–997.
54. Miller, MR, Peters, TR, Suerken, CK, Snively, BM, Poehling, KA, Predictors of influenza diagnosis among patients with laboratory-confirmed influenza. J Infect Dis 212 (2015), 1604–1612.
55. Monto, AS, Gravenstein, S, Elliott, M, Colopy, M, Schweinle, J, Clinical signs and symptoms predicting influenza infection. Arch Intern Med 160 (2000), 3243–3247.
56. Peltola, V, Reunanen, T, Ziegler, T, Silvennoinen, H, Heikkinen, T, Accuracy of clinical diagnosis of influenza in outpatient children. Clin Infect Dis 41 (2005), 1198–1200.
57. Bouscambert, M, Valette, M, Lina, B, Rapid bedside tests for diagnosis, management, and prevention of nosocomial influenza. J Hosp Infect 89 (2015), 314–318.
58. Kim, DK, Poudel, B, Tools to detect influenza virus. Yonsei Med J 54 (2013), 560–566.
59. Peaper, DR, Landry, ML, Rapid diagnosis of influenza: state of the art. Clin Lab Med 34 (2014), 365–385.
60. Petrozzino, JJ, Smith, C, Atkinson, MJ, Rapid diagnostic testing for seasonal influenza: an evidence-based review and comparison with unaided clinical diagnosis. J Emerg Med, 39, 2010, 476 90.e1.
61. Ohkura, N, Tani, M, Nishitsuji, M, Nishi, K, Primary A (H1N1) pdm09 influenza pneumonia diagnosed on reverse transcription-polymerase chain reaction (RT-PCR) of bronchoalveolar lavage fluid but not rapid tests with nasopharyngeal swabs. Intern Med 54 (2015), 1441–1445.
62. Ison, MG, Optimizing antiviral therapy for influenza: understanding the evidence. Expert Rev Anti Infect Ther 13 (2015), 417–425.
63. Hayden, FG, Hay, AJ, Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 176 (1992), 119–130.
64. Committee on Infectious Diseases American Academy of Pediatrics. Recommendations for prevention and control of influenza in children, 2015–2016. Pediatrics 136 (2015), 792–808.
65. Beigel, J, Bray, M, Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res 78 (2008), 91–102.
66. Meijer, A, Rebelo-de-Andrade, H, Correia, V, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012–2013. Antiviral Res 110 (2014), 31–41.
67. Gulati, S, Smith, DF, Air, GM, Deletions of neuraminidase and resistance to oseltamivir may be a consequence of restricted receptor specificity in recent H3N2 influenza viruses. Virol J, 6, 2009, 22.
68. Takashita, E, Kiso, M, Fujisaki, S, et al. Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013–2014 influenza season in Japan. Antimicrob Agents Chemother 59 (2015), 2607–2617.
69. Dobson, J, Whitley, RJ, Pocock, S, Monto, AS, Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 385 (2015), 1729–1737.
70. Jefferson, T, Jones, M, Doshi, P, Spencer, EA, Onakpoya, I, Heneghan, CJ, Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ, 348, 2014, g2545.
71. Jefferson, T, Jones, MA, Doshi, P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev, 4, 2014, CD008965.
72. Jones, M, Jefferson, T, Doshi, P, Del Mar, C, Heneghan, C, Onakpoya, I, Commentary on Cochrane review of neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Clin Microbiol Infect 21 (2015), 217–221.
73. Okoli, GN, Otete, HE, Beck, CR, Nguyen-Van-Tam, JS, Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies. PLoS One, 9, 2014, e113633.
74. Fry, AM, Goswami, D, Nahar, K, et al. Effects of oseltamivir treatment of index patients with influenza on secondary household illness in an urban setting in Bangladesh: secondary analysis of a randomised, placebo-controlled trial. Lancet Infect Dis 15 (2015), 654–662.
75. Nguyen-Van-Tam, JS, Openshaw, PJM, Nicholson, KG, Antivirals for influenza: where now for clinical practice and pandemic preparedness?. Lancet 384 (2014), 386–387.
76. Muthuri, SG, Venkatesan, S, Myles, PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2 (2014), 395–404.
77. Chaves, SS, Perez, A, Miller, L, et al. Impact of prompt influenza antiviral treatment on extended care needs after influenza hospitalization among community-dwelling older adults. Clin Infect Dis 61 (2015), 1807–1814.
78. McQuade, B, Blair, M, Influenza treatment with oseltamivir outside of labeled recommendations. Am J Health Syst Pharm 72 (2015), 112–116.
79. Welch, SC, Lam, SW, Neuner, EA, Bauer, SR, Bass, SN, High-dose versus standard dose oseltamivir for treatment of severe influenza in adult intensive care unit patients. Intensive Care Med 41 (2015), 1365–1366.
80. Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians. https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm, 2017 Feb 1, (accessed Feb 23, 2017).
81. Dunning, J, Baillie, JK, Cao, B, Hayden, FG, on behalf of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). Antiviral combinations for severe influenza. Lancet Infect Dis 14 (2014), 1259–1270.
82. Gasparini, R, Amicizia, D, Lai, PL, Bragazzi, NL, Panatto, D, Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: future compounds against influenza virus. J Prev Med Hyg 55 (2014), 109–129.
83. Mehrbod, P, Omar, AR, Hair-Bejo, M, Haghani, A, Ideris, A, Mechanisms of action and efficacy of statins against influenza. Biomed Res Int, 2014, 2014, 872370.
84. Kakeya, H, Seki, M, Izumikawa, K, et al. Efficacy of combination therapy with oseltamivir phosphate and azithromycin for influenza: a multicenter, open-label, randomized study. PLoS One, 9, 2014, e91293.
85. Rodrigo, C, Leonardi-Bee, J, Nguyen-Van-Tam, J, Lim, WS, Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev, 3, 2016, CD010406.
86. Zhang, Y, Sun, W, Svendsen, ER, et al. Do corticosteroids reduce the mortality of influenza A (H1N1) infection? A meta-analysis. Crit Care, 19, 2015, 46.
87. Byrn, RA, Jones, SM, Bennett, HB, et al. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob Agents Chemother 59 (2015), 1569–1582.
88. Krol, E, Rychlowska, M, Szewczyk, B, Antivirals—current trends in fighting influenza. Acta Biochim Pol 61 (2014), 495–504.
89. Pelegrin, M, Naranjo-Gomez, M, Piechaczyk, M, Antiviral monoclonal antibodies: can they be more than simple neutralizing agents?. Trends Microbiol 23 (2015), 653–665.
90. Ramos, EL, Mitcham, JL, Koller, TD, et al. Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza. J Infect Dis 211 (2015), 1038–1044.
91. Zenilman, JM, Fuchs, EJ, Hendrix, CW, et al. Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults. Antiviral Res 123 (2015), 114–119.
92. Gasparini, R, Amicizia, D, Lai, PL, Bragazzi, NL, Panatto, D, Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part I: influenza life-cycle and currently available drugs. J Prev Med Hyg 55 (2014), 69–85.
93. Houser, K, Subbarao, K, Influenza vaccines: challenges and solutions. Cell Host Microbe 17 (2015), 295–300.
94. Grohskopf, LA, Sokolow, LZ, Olsen, SJ, Bresee, JS, Broder, KR, Karron, RA, Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015–16 influenza season. MMWR Morb Mortal Wkly Rep 64 (2015), 818–825.
95. Rhorer, J, Ambrose, CS, Dickinson, S, et al. Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. Vaccine 27 (2009), 1101–1110.
96. Black, CL, Yue, X, Ball, SW, et al. Influenza vaccination coverage among health care personnel—United States, 2014–15 influenza season. MMWR Morb Mortal Wkly Rep 64 (2015), 993–999.
97. Jin, H, Subbarao, K, Live attenuated influenza vaccine. Curr Top Microbiol Immunol 386 (2015), 181–204.
98. Ashkenazi, S, Vertruyen, A, Aristegui, J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 25 (2006), 870–879.
99. Gaglani, M, Pruszynski, J, Murthy, K, et al. Influenza vaccine effectiveness against 2009 pandemic influenza A (H1N1) virus differed by vaccine type during 2013–2014 in the United States. J Infect Dis 213 (2016), 1546–1556.
100. Pebody, R, Warburton, F, Ellis, J, et al. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. Euro Surveill, 21, 2016, 30348.
101. Sullivan, SG, Feng, S, Cowling, BJ, Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review. Expert Rev Vaccines 13 (2014), 1571–1591.
102. Jefferson, T, Di Pietrantonj, C, Rivetti, A, Bawazeer, GA, Al-Ansary, LA, Ferroni, E, Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev, 3, 2014, CD001269.
103. Osterholm, MT, Kelley, NS, Sommer, A, Belongia, EA, Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12 (2012), 36–44.
104. Chan, TC, Fan-Ngai, Hung I, Ka-Hay, Luk J, Chu, LW, Hon-Wai, Chan F, Effectiveness of influenza vaccination in institutionalized older adults: a systematic review. J Am Med Dir Assoc 15 (2014), 226.e1–226.e6.
105. Beck, CR, McKenzie, BC, Hashim, AB, et al. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis 206 (2012), 1250–1259.
106. Lee, WJ, Chen, LK, Tang, GJ, Lan, TY, The impact of influenza vaccination on hospitalizations and mortality among frail older people. J Am Med Dir Assoc 15 (2014), 256–260.
107. Reed, C, Kim, IK, Singleton, JA, et al. Estimated influenza illnesses and hospitalizations averted by vaccination—United States, 2013–14 influenza season. MMWR Morb Mortal Wkly Rep 63 (2014), 1151–1154.
108. Neuzil, KM, How can we solve the enigma of influenza vaccine-induced protection?. J Infect Dis 211 (2015), 1517–1518.
109. DiazGranados, CA, Dunning, AJ, Robertson, CA, Talbot, HK, Landolfi, V, Greenberg, DP, Effect of previous-year vaccination on the efficacy, immunogenicity, and safety of high-dose inactivated influenza vaccine in older adults. Clin Infect Dis 62 (2016), 1092–1099.
110. Ding, H, Black, CL, Ball, S, et al. Influenza vaccination coverage among pregnant women—United States, 2014–15 influenza season. MMWR Morb Mortal Wkly Rep 64 (2015), 1000–1005.
111. Steinhoff, MC, MacDonald, N, Pfeifer, D, Muglia, LJ, Influenza vaccine in pregnancy: policy and research strategies. Lancet 383 (2014), 1611–1613.
112. Fell, DB, Platt, RW, Lanes, A, et al. Fetal death and preterm birth associated with maternal influenza vaccination: systematic review. Brit J Obstet Gynaec 122 (2015), 17–26.
113. Keller-Stanislawski, B, Englund, JA, Kang, G, et al. Safety of immunization during pregnancy: a review of the evidence of selected inactivated and live attenuated vaccines. Vaccine 32 (2014), 7057–7064.
114. Naleway, AL, Irving, SA, Henninger, ML, et al. Safety of influenza vaccination during pregnancy: a review of subsequent maternal obstetric events and findings from two recent cohort studies. Vaccine 32 (2014), 3122–3127.
115. Lambert, LC, Fauci, AS, Influenza vaccines for the future. N Engl J Med 363 (2010), 2036–2044.
116. Camilloni, B, Basileo, M, Valente, S, Nunzi, E, Iorio, AM, Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: a literature review. Hum Vaccin Immunother 11 (2015), 553–563.
117. Nolan, T, Roy-Ghanta, S, Montellano, M, et al. Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial. J Infect Dis 210 (2014), 545–557.
118. Nohynek, H, Jokinen, J, Partinen, M, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One, 7, 2012, e33536.
119. Miller, E, Andrews, N, Stellitano, L, et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ, 346, 2013, f794.
120. Krammer, F, Emerging influenza viruses and the prospect of a universal influenza virus vaccine. Biotechnol J 10 (2015), 690–701.
121. Lee, YT, Kim, KH, Ko, EJ, et al. New vaccines against influenza virus. Clin Exp Vaccine Res 3 (2014), 12–28.
122. Yoon, SW, Webby, RJ, Webster, RG, Evolution and ecology of influenza A viruses. Curr Top Microbiol Immunol 385 (2014), 359–375.
123. Salomon, R, Webster, RG, The influenza virus enigma. Cell 136 (2009), 402–410.
124. Neumann, G, Kawaoka, Y, Transmission of influenza A viruses. Virology 479–480 (2015), 234–246.
125. Subbarao, EK, London, W, Murphy, BR, A single amino acid in the PB2 gene of influenza A virus is a determinant of host range. J Virol 67 (1992), 1761–1764.
126. Subbarao, K, Klimov, A, Katz, J, et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279 (1998), 393–396.
127. Van, Kerkhove MD, Brief literature review for the WHO global influenza research agenda—highly pathogenic avian influenza H5N1 risk in humans. Influenza Other Respir Viruses 7:suppl 2 (2013), 26–33.
128. Beigel, JH, Farrar, J, Han, AM, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 353 (2005), 1374–1385.
129. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H1N1) Virus. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 358 (2008), 261–273.
130. Hui, DS, Review of clinical symptoms and spectrum in humans with influenza A/H5N1 infection. Respirology 13:suppl 1 (2008), 10–13.
131. Freidl, GS, Meijer, A, de Bruin, E, et al. Influenza at the animal-human interface: a review of the literature for virological evidence of human infection with swine or avian influenza viruses other than A(H5N1). Euro Surveill, 19, 2014, 20793.
132. Gao, R, Cao, B, Hu, Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 368 (2013), 1888–1897.
133. Farooqui, A, Liu, W, Kelvin, DJ, et al. Probable hospital cluster of H7N9 influenza infection. N Engl J Med 374 (2016), 596–598.
134. Tanner, WD, Toth, DJ, Gundlapalli, AV, The pandemic potential of avian influenza A(H7N9) virus: a review. Epidemiol Infect 143 (2015), 3359–3374.
135. Marjuki, H, Mishin, VP, Chesnokov, AP, et al. Neuraminidase mutations conferring resistance to oseltamivir in influenza A(H7N9) viruses. J Virol 89 (2015), 5419–5426.
136. Li, X, Shi, J, Guo, J, et al. Genetics, receptor binding property, and transmissibility in mammals of naturally isolated H9N2 avian influenza viruses. PLoS Pathog, 10, 2014, e1004508.
137. Pu, J, Wang, S, Yin, Y, et al. Evolution of the H9N2 influenza genotype that facilitated the genesis of the novel H7N9 virus. Proc Natl Acad Sci USA 112 (2015), 548–553.
138. Rajao, DS, Gauger, PC, Anderson, TK, et al. Novel reassortant human-like H3N2 and H3N1 influenza A viruses detected in pigs are virulent and antigenically distinct from swine viruses endemic to the United States. J Virol 89 (2015), 11213–11222.
139. Cauchemez, S, Epperson, S, Biggerstaff, M, Swerdlow, D, Finelli, L, Ferguson, NM, Using routine surveillance data to estimate the epidemic potential of emerging zoonoses: application to the emergence of US swine origin influenza A H3N2v virus. PLoS Med, 10, 2013, e1001399.